Actavis Singapore, (formerly Drug Houses of Australia) is a subsidiary of Actavis plc.
Actavis plc is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
The company has commercial operations in approximately 60 countries and more than 30 manufacturing and distribution facilities around the world, including two in Asia, in Singapore and Indonesia.
Actavis recently announced the proposed acquisition of Forest Laboratories. If the transaction is completed, the combination of Actavis and Forest will create an innovative new model in specialty pharmaceuticals leadership, with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development and the ability to drive sustainable organic growth.
The combined company would have expected annual revenues of approximately US$15billion.
|Actavis in Asia|
The official opening of Actavis’ regional commercial office in Singapore on April 3, 2014, is a significant step in the continued global expansion of Actavis.
Regionally, Actavis has leading positions in Singapore, Hong Kong, Australia and New Zealand, and is quickly growing in Vietnam and Malaysia. In 2013, Actavis launched more than 70 new products and filed more than 85 applications for new products within the region.
The company looks forward to strengthening our operations in emerging markets across
Southeast Asia, enabling consumers to have increased access to the high-quality medicines that help them live longer, healthier lives.
Actavis Singapore Pte Ltd, formerly DHA, markets premium products, manufactured at our own facilities in Singapore and at other global sites via contract manufacturing. We ensure consistent high quality and reliability in every single product, and our manufacturing sites include those approved by stringent requirements of regulatory authorities such as USFDA, TGA & MHRA.